Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BMO Capital Maintains Outperform on Morphic Holding, Lowers Price Target to $52

Author: Benzinga Newsdesk | September 28, 2023 08:29am
BMO Capital analyst Evan David Seigerman maintains Morphic Holding (NASDAQ:MORF) with a Outperform and lowers the price target from $106 to $52.

Posted In: MORF

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist